TORONTO, July 17, 2013 /CNW/ - Amorfix Life Sciences, a product
development company focused on diagnostics and therapeutics for
misfolded protein diseases, today announced that Dr. Neil Cashman,
Amorfix Co-founder and Chief Scientific Officer, will be presenting an
update of the Company's ALS diagnostic assay at the 24th International Symposium on MND/ALS being held in Milan, ItalyDecember
6-8, 2013.

"This international conference represents an excellent forum for Amorfix
to highlight recent progress on our ground-breaking, simple blood test
for the early diagnosis of ALS", said Dr. Robert Gundel, Amorfix
President and Chief Executive Officer. The International Symposium on
MND/ALS is the largest medical and scientific conference on motor
neuron disease and is attended by more than 800 delegates from academia
and the pharmaceutical industry. Dr. Cashman will provide an overview
of the Company's novel diagnostic blood test that measures levels of
misfolded superoxide dismutase 1 (mSOD1) in the plasma of ALS
patients. Preliminary data have shown that mSOD1 is present and
measurable in the plasma of ALS patients but not detectable in normal
subjects. The Company is using its proprietary antibodies and AMFIA
technology to develop a simple and rapid blood test that will identify
patients with early-stage disease.

ALS is a disease that is difficult to diagnose and treat. At the
present time, clinicians must rely on a combination of clinical
findings and indirect testing to confirm a diagnosis of ALS, as there
is no diagnostic test or biomarker at their disposal. The average
survival time after diagnosis is 3 to 5 years, and there are very few
treatment options available for patients once diagnosed with ALS. The
Company believes that the availability of a reliable blood test would
represent an important advancement in the management of this
devastating disease, allowing clinicians to diagnose the disease
earlier and provide better treatment. The projected market for such a
diagnostic test is approximately $250M/year.

About ALS
ALS is a common neuromuscular disease, affecting an estimated 120,000
people of all races and ethnic backgrounds worldwide. According to the
ALS Association, more than 5,600 people in the U.S. are diagnosed with
ALS annually and an estimated 30,000 Americans have ALS at any given
time.

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection and
AMFIA, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a cerebrospinal fluid (CSF) screening test
for both Alzheimer's disease (AD) and mild cognitive impairment (MCI),
and an ultrasensitive method for detecting the hallmark of AD,
aggregated beta-Amyloid, in brain tissue, CSF and blood from animal
models of AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise.